Peter Bains
#353Managing Director & CEO
67
Age
46y
Exp
7y
Tenure
6/10
Risk
🎓 B.Sc. in Zoology and Physiology · University of Sheffield
📜 — · —
🏛️ None
CompensationTBP
Personality
7
Open
6
Cons
5
Extr
6
Agre
3
Neur
Syngene Intl.
Healthcare · Mid Cap
High Growth · Innovation-Led
About
Peter Bains is the Managing Director & CEO of Syngene Intl., a Mid Cap company in the Healthcare sector with a market cap of ₹16K Cr. A Visionary leader with 46 years of experience, he is known for authority-driven decision-making and partnership seeker strategy. Emphasizes long-term scientific collaboration and infrastructure investment to scale global contract research capabilities.
FAQ
What is Peter Bains's leadership style?
Peter Bains is classified as a Visionary leader. He is authority-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Peter Bains's educational background?
Peter Bains holds a B.Sc. in Zoology and Physiology from University of Sheffield and a — from —.
Who is the CEO of Syngene Intl.?
Peter Bains is the Managing Director & CEO of Syngene Intl.. He has been with the company for 7 years and in the current role for 7 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisSteady Hand
DecisionAuthority-Driven
GrowthPartnership Seeker
PeopleInstitution Builder
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Emphasizes long-term scientific collaboration and infrastructure investment to scale global contract research capabilities.”
⚡ Crisis●●●○○
During his tenure, Bains maintained Syngene's long-term R&D investment strategy and operational continuity despite global supply chain disruptions.
🎯 Motivation●●●●○
He transformed Syngene from a service provider into a global innovation-led research partner by focusing on high-end discovery services and proprietary platforms.
👥 People●●●○○
He prioritized building a robust scientific talent pipeline and internal R&D infrastructure to sustain Syngene's position as a research-led organization.
📈 Growth●●●●●
Syngene's growth has been defined by long-term strategic collaborations with global giants like Bristol Myers Squibb and Amgen.
💡 Innovation●●●●○
As a Contract Research Organization, Syngene excels by scaling and executing complex drug discovery and development processes for global pharma clients rather than creating its own proprietary end-market products.
🏃 Pace●●●●○
The business operates on long-term, multi-year strategic research collaborations and manufacturing contracts that require methodical, consistent, and predictable delivery.
🌱 Purpose●●●●○
The company integrates rigorous ESG reporting and sustainability goals into its operational strategy, reflecting its role in advancing global healthcare outcomes for its partners.
🏷️ Brand●●●●●
Syngene is defined by its deep scientific capabilities and specialized technical infrastructure, positioning it as a highly respected, expert partner in the global drug discovery value chain.
🤝 Customer●●●●●
Syngene operates exclusively as a service provider for global pharmaceutical, biotechnology, and nutrition companies through long-term enterprise partnerships.
💼 Employer●●●●○
The company is recognized for its massive investment in scientific talent development and high-end laboratory infrastructure, serving as a premier training ground for research scientists in India.
📋 Mandate
Continuous investment in R&D capacity and complex service delivery requires leadership focused on scientific efficiency and global client acquisition.
🏢 Culture●●●●○
R&D-focused contract research organization requiring a culture of experimentation and precision.
Financials
Revenue FY25₹4K Cr
PAT FY25₹496 Cr
Rev CAGR 5Y11.9%
OPM17.5%
NPM14.1%
ROE10.5%
ROCE11.4%
P/E48.1
Fwd P/E36.8
P/B3.6
D/E12.3
Promoter53.1%
Institutional36.3%
Mkt Cap₹16K Cr
Compensation
To Be Published
Data being verified from audited reports
